Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDM-180935 in Atopic Dermatitis
NCT06363461Phase 2Completed
- Sponsor
- TechnoDerma Medicines Inc.
- Start
- Apr 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tdm-180935 in atopic dermatitis (AD) (5 arms), sponsored by TechnoDerma Medicines Inc. Primary endpoint: Change in modified Eczema Area and Severity Index score at 8 weeks. Started Apr 2024; status: completed.
02
Drugs
tdm-180935
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06363461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06363461.